Invasive potential of "noninvasive" human bladder carcinoma. An electron microscopy study.

Am J Clin Pathol

Department of Urology, St Franziskus Hospital, Rheinisch Westfälische Technische Hochschule University of Aachen, Triererstrasse 176/178, D-52078 Aachen, Germany.

Published: August 2003

In classification systems for bladder tumors, a clear distinction between superficial noninvasive and urothelial carcinoma invasive to the lamina propria is of prognostic and therapeutic significance. However, a subset of tumors classified as noninvasive is characterized by increased recurrence and progression rates. This study was done to look for ultrastructural characteristics in histopathologically noninvasive urothelial bladder carcinomas that might predict an unfavorable prognosis. In 10 (83%) of 12 bladder tumors studied extensively, electron microscopy revealed the presence of different degrees of lamina propria penetration by individual tumor cells (microlesions and microinvasions). In 10 (77%) of 13 "normal" control tissues, no such lesions or microinvasions were detected. These findings indicate that ultrastructural analysis may contribute to more precise staging of superficial bladder carcinoma. Undetected microinvasions may explain more aggressive biologic behavior in a subset of bladder tumors classified as noninvasive by conventional histopathologic assessment.

Download full-text PDF

Source
http://dx.doi.org/10.1309/11XT-P4X4-J1HB-LMNGDOI Listing

Publication Analysis

Top Keywords

bladder tumors
12
bladder carcinoma
8
electron microscopy
8
noninvasive urothelial
8
lamina propria
8
tumors classified
8
classified noninvasive
8
bladder
6
invasive potential
4
potential "noninvasive"
4

Similar Publications

URINARY BLADDER PARAGANGLIOMA- A NOTEWORTHY, RARE ENTITY.

Acta Endocrinol (Buchar)

January 2025

All India Institute of Medical Science, Department of Pathology & Lab Medicine, Mangalagiri, Guntur, India.

Unlabelled: Urinary Bladder paraganglioma accounts for 0.06% of all bladder tumors and 1% of all pheochromocytoma. Most tumors are localized at the dome or trigone and are unifocal.

View Article and Find Full Text PDF

Bacillus Calmette-Guerin (BCG) infections following intravesical BCG immunotherapy: a systematic review protocol.

Syst Rev

January 2025

Department of Medicine, Division of Infectious Diseases, Duke University, 148 Hanes House, 315 Trent Dr, Durham, NC, 27710, USA.

Background: Although intravesical Bacillus Calmette-Guerin (BCG) immunotherapy usually exhibits a favorable safety profile, it can lead to the development of BCG infections, both localized and disseminated. Understanding of BCG infections following intravesical BCG immunotherapy is limited because of the lack of consensus definitions of BCG infections and limited post-instillation follow-up. We aim to perform a systematic review of the literature of BCG infections following intravesical BCG immunotherapy to elucidate the epidemiology, risk factors, and outcomes of BCG infections.

View Article and Find Full Text PDF

Background: With over 80,000 projected new diagnoses in 2024, bladder cancer remains a significant public health concern. Given the absence of routine screening protocols, identifying high-risk populations becomes crucial for early detection and intervention. This study aimed to investigate whether race and ethnicity modify the association between sex and stage at diagnosis in adults with primary bladder cancer.

View Article and Find Full Text PDF

Background: To reduce the mortality related to bladder cancer, efforts need to be concentrated on early detection of the disease for more effective therapeutic intervention. Strong risk factors (eg, smoking status, age, professional exposure) have been identified, and some diagnostic tools (eg, by way of cystoscopy) have been proposed. However, to date, no fully satisfactory (noninvasive, inexpensive, high-performance) solution for widespread deployment has been proposed.

View Article and Find Full Text PDF

Importance: Three similar phase 3 randomized clinical trials have investigated PD-1/PD-L1 (programmed cell death 1 protein/programmed cell death 1 ligand 1) inhibitors in combination with platinum-based chemotherapy vs chemotherapy alone as first-line treatment for advanced urothelial carcinoma (IMvigor130, atezolizumab; KEYNOTE-361, pembrolizumab; and CheckMate901, nivolumab). Only CheckMate901 reported overall survival (OS) benefit for the combination. The reason for these inconsistent results is unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!